within Pharmacolibrary.Drugs.ATC.N;

model N06AX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.022000000000000002,
    adminDuration  = 600,
    adminMass      = 0.7,
    adminCount     = 1,
    Vd             = 0.0076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Viloxazine is a selective norepinephrine reuptake inhibitor that was originally developed and used as an antidepressant in several European countries. It is now approved by the US FDA as a non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after single oral administration.</p><h4>References</h4><ol><li>Azmi Nasser, Roberto Gomeni, Zhao Wang, Alisa R Kosheleff, Lanyi Xie, Lilian W Adeojo, Stefan Schwabe,Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.,Journal of clinical pharmacology,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34269426/'>https://pubmed.ncbi.nlm.nih.gov/34269426/</a></li><li>Shamia L Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Stefan Schwabe, Zhao Wang, Vladimir Maletic, Azmi Nasser,Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults.,Clinical drug investigation,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33368026/'>https://pubmed.ncbi.nlm.nih.gov/33368026/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AX09;
